Bruising associated with sibutramine: Results from postmarketing surveillance in New Zealand

International Journal of Obesity

Volumn 30, Issue 8, 2006, Pages 1315-1317

  Harrison Woolrych, M ^a   Hill, G R ^a   Clark, D W J ^b  

^a UNIVERSITY OF OTAGO   (New Zealand)

^b UNIVERSITY OF OTAGO   (New Zealand)

Author keywords

Bleeding; Bruising; Pharmacovigilance; Serotonin reuptake inhibitors; Sibutramine

Indexed keywords

NORADRENALIN UPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; SIBUTRAMINE;

ADULT; AGED; ARTICLE; BLEEDING; BRUISING; CLINICAL ARTICLE; DRUG SURVEILLANCE PROGRAM; FEMALE; HUMAN; NEW ZEALAND; OBESITY; POSTMARKETING SURVEILLANCE; PRIORITY JOURNAL; TREATMENT OUTCOME; WORLD HEALTH ORGANIZATION;

ADULT; ADVERSE DRUG REACTION REPORTING SYSTEMS; APPETITE DEPRESSANTS; CONTUSIONS; CYCLOBUTANES; FEMALE; HUMANS; MIDDLE AGED; NEW ZEALAND; PRODUCT SURVEILLANCE, POSTMARKETING; WORLD HEALTH ORGANIZATION;

EID: 33746554815     PISSN: 03070565     EISSN: 14765497     Source Type: Journal    
DOI: 10.1038/sj.ijo.0803268     Document Type: Article

References (18)

1. Wolfe S, Sasich L, Barbehenn E. Petition to FDA to ban the diet drug sibutramine (MERIDIA) (HRG Publication #1613). Public Citizen Health Research Group Available at: http://www.citizen.org/publications/print_release.cfm? ID7160, accessed 1 September, 2005.
2. Rubin R. Concern about drug safety doesn't stop with Vioxx. USA Today November 22, 2004; D: 7.
3. Saul S. US allows continued sale of Abbott weight-loss drug. The New York Times August 18, 2005.
4. Corbett Dooren J. FDA rejects public citizen petition to Ban Meridia. Dow Jones & Company 2000. [Dow Jones Newswires]. Available at: http://news.morningstar.com/news/, accessed 5 September, 2005.
5. Layton D, Clark D, Pearce G, Shakir S. Is there an association between Selective Serotonin Reuptake Inhibitors (SSRI) and risk of abnormal bleeding? Results from a cohort study based on Prescription Event Monitoring (PEM) in England and Wales. Eur J Clin Pharmacol 2001; 57: 167-176.
6. Paton C, Ferrier IN. SSRIs and gastrointestinal bleeding. BMJ 2005; 331: 529-530.
7. Abbott Laboratories. Meridia product information. Abbott Laboratories December 2004. Available at: www.meridia.net, accessed 12 August 2005, 2005.
8. Coulter D. PEM in New Zealand. In: Andrews E (ed). Pharmacovigilance. JohnWiley& Sons: Chichester, England, 2002, pp 345-362.
9. Meyboom R, Lindquist M, Egberts ACG, Edwards I. Signal selection and follow-up in pharmacovigilance. Drug Safety 2002; 25: 459-465.
10. WHO Collaborating Centre for International Drug Monitoring. The WHO Programme for International Drug Monitoring. Available at: http://www.who-umc. org, accessed 5 December, 2005.
11. Thomson MICROMEDEX. Physicians' Desk Reference. Micromedex (R) Healthcare Series [website]. Available at: http://micromedex.prioinfo.se 2005.
12. de Abajo FJ, Jick H, Derby L, Jick S, Schmitz S. Intracranial haemorrhage and use of selective serotonin reuptake inhibitors. Br J Clin Pharmacol 2000; 50: 43-47.
13. Yaryura-Tobias J, Kirschen H, Ninan P, Mosberg H. Fluoxetine and bleeding in obsessive-compulsive disorder. Am J Psychiatry 1991; 148: 949.
14. Calhoun JW, Calhoun DD. Prolonged bleeding time in a patient treated with sertraline. Am J Psychiatry 1996; 153: 443.
15. Abbott Laboratories. Reductil data sheet. Medsafe,August 2004. Available at: http://www.medsafe.govt.nz/profs/Datasheet/r/Reductilcap.htm, accessed 5 July 2005, 2005.
16. Dalton SO, Johansen C, Mellemkjaer L, Sorensen HT, Norgard B, Olsen JH. Use of selective serotonin reuptake inhibitors and risk of upper gastrointestinal tract bleeding: a population-based cohort study. Arch Intern Med 2003; 163: 59-64.
17. van Walraven C, Mamdani MM, Wells PS, Williams JI. Inhibition of serotonin reuptake by antidepressants and upper gastrointestinal bleeding in elderly patients: retrospective cohort. BMJ 2001; 323: 655-658.
18. Meijer WEE, Heerdink ER, Nolen WA, Herings RMC, Leufkens HGM, Egberts ACG. Association of risk of abnormal bleeding with degree of serotonin reuptake inhibition by antidepressants. Arch Intern Med 2004; 164: 2367-2370.